398 related articles for article (PubMed ID: 31846042)
1. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
4. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
Atemnkeng Ntam V; Klein A; Horneff G
Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
[No Abstract] [Full Text] [Related]
6. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
Horneff G
Expert Opin Drug Saf; 2015 Jul; 14(7):1111-26. PubMed ID: 26084637
[TBL] [Abstract][Full Text] [Related]
7. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
Minden K; Klotsche J; Niewerth M; Horneff G; Zink A
Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
10. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.
Thiele F; Klein A; Windschall D; Hospach A; Foeldvari I; Minden K; Weller-Heinemann F; Horneff G
Rheumatol Int; 2021 Apr; 41(4):751-762. PubMed ID: 33590331
[TBL] [Abstract][Full Text] [Related]
11. Incident psoriasis under treatment with tumor necrosis factor-α inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry.
Zimmer A; Klein A; Kuemmerle-Deschner JB; Dressler F; Onken N; Brueck N; Fasshauer M; Hospach T; Hufnagel M; Foell D; Horneff G
Rheumatol Int; 2023 Sep; 43(9):1675-1684. PubMed ID: 37291093
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
[TBL] [Abstract][Full Text] [Related]
13. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
Becker I; Horneff G
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
[TBL] [Abstract][Full Text] [Related]
14. Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry.
Klein A; Becker I; Minden K; Hospach A; Schwarz T; Foeldvari I; Huegle B; Borte M; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner J; Oommen PT; Foell D; Trauzeddel R; Rietschel C; Horneff G
ACR Open Rheumatol; 2020 Jan; 2(1):37-47. PubMed ID: 31943968
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL
Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641
[TBL] [Abstract][Full Text] [Related]
16. Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER.
Bethencourt Baute JJ; Sanchez-Piedra C; Ruiz-Montesinos D; Medrano San Ildefonso M; Rodriguez-Lozano C; Perez-Pampin E; Ortiz A; Manrique S; Roselló R; Hernandez V; Campos C; Sellas A; Sifuentes-Giraldo WA; García-González J; Sanchez-Alonso F; Díaz-González F; Gómez-Reino JJ; Bustabad Reyes S;
Arthritis Res Ther; 2018 Oct; 20(1):227. PubMed ID: 30305158
[TBL] [Abstract][Full Text] [Related]
17. Biologic-associated infections in pediatric rheumatology.
Horneff G
Curr Rheumatol Rep; 2015 Nov; 17(11):66. PubMed ID: 26385753
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.
Barthel D; Ganser G; Kuester RM; Onken N; Minden K; Girschick HJ; Hospach A; Horneff G
J Rheumatol; 2015 Nov; 42(11):2160-5. PubMed ID: 26373564
[TBL] [Abstract][Full Text] [Related]
19. Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis.
Hinze C; Fuehner S; Kessel C; Wittkowski H; Lainka E; Baehr M; Hügle B; Haas JP; Ganser G; Weißbarth-Riedel E; Jansson A; Foell D
Arthritis Rheumatol; 2020 Mar; 72(3):499-505. PubMed ID: 31599092
[TBL] [Abstract][Full Text] [Related]
20. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]